Landfar Bio-medicine Co., Ltd

SZSE:000504 Rapport sur les actions

Capitalisation boursière : CN¥3.5b

Landfar Bio-medicine Résultats passés

Passé contrôle des critères 0/6

Landfar Bio-medicine's earnings have been declining at an average annual rate of -50.7%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been declining at an average rate of 0.03% per year.

Informations clés

-50.7%

Taux de croissance des bénéfices

-50.7%

Taux de croissance du BPA

Biotechs Croissance de l'industrie11.3%
Taux de croissance des recettes-0.03%
Rendement des fonds propres-20.0%
Marge nette-29.8%
Dernière mise à jour des bénéfices30 Sep 2024

Mises à jour récentes des performances passées

Recent updates

There's Reason For Concern Over Landfar Bio-medicine Co., Ltd's (SZSE:000504) Massive 37% Price Jump

Oct 21
There's Reason For Concern Over Landfar Bio-medicine Co., Ltd's (SZSE:000504) Massive 37% Price Jump

Risks Still Elevated At These Prices As Landfar Bio-medicine Co., Ltd (SZSE:000504) Shares Dive 31%

Jun 09
Risks Still Elevated At These Prices As Landfar Bio-medicine Co., Ltd (SZSE:000504) Shares Dive 31%

Landfar Bio-medicine Co., Ltd's (SZSE:000504) Popularity With Investors Under Threat As Stock Sinks 32%

Apr 17
Landfar Bio-medicine Co., Ltd's (SZSE:000504) Popularity With Investors Under Threat As Stock Sinks 32%

Landfar Bio-medicine Co., Ltd (SZSE:000504) Investors Are Less Pessimistic Than Expected

Mar 01
Landfar Bio-medicine Co., Ltd (SZSE:000504) Investors Are Less Pessimistic Than Expected

Ventilation des recettes et des dépenses

Comment Landfar Bio-medicine gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.


Historique des gains et des recettes

SZSE:000504 Recettes, dépenses et bénéfices (CNY Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
30 Sep 24124-3710713
30 Jun 24123-2811312
31 Mar 24128-2911313
31 Dec 23137-2811613
30 Sep 23149-1312910
30 Jun 23161-2413110
31 Mar 23170-1513110
31 Dec 22200-1213710
30 Sep 22210-101219
30 Jun 22199-111219
31 Mar 22188-201279
01 Jan 22157-191229
30 Sep 211743988
30 Jun 212014896
31 Mar 2119011775
31 Dec 201768695
30 Sep 20149355812
30 Jun 20116316412
31 Mar 20123247113
31 Dec 19134197616
30 Sep 19130-328018
30 Jun 19120-347319
31 Mar 19108-346818
31 Dec 1895-356016
30 Sep 18106-40667
30 Jun 1889-41576
31 Mar 1882-39474
31 Dec 1767-37413
30 Sep 177217312
30 Jun 177622290
31 Mar 176922290
31 Dec 166722280
30 Sep 1616-27270
30 Jun 1613-26250
31 Mar 1614-22220
31 Dec 1513-21210
30 Sep 1515-23220
30 Jun 1515-24210
31 Mar 1516-25230
31 Dec 1418-26250
30 Sep 142316230
30 Jun 142518240
31 Mar 142717220
31 Dec 132614220

Des revenus de qualité: 000504 is currently unprofitable.

Augmentation de la marge bénéficiaire: 000504 is currently unprofitable.


Analyse des flux de trésorerie disponibles par rapport aux bénéfices


Analyse de la croissance passée des bénéfices

Tendance des revenus: 000504 is unprofitable, and losses have increased over the past 5 years at a rate of 50.7% per year.

Accélération de la croissance: Unable to compare 000504's earnings growth over the past year to its 5-year average as it is currently unprofitable

Bénéfices par rapport au secteur d'activité: 000504 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.08%).


Rendement des fonds propres

ROE élevé: 000504 has a negative Return on Equity (-20.04%), as it is currently unprofitable.


Rendement des actifs


Rendement des capitaux employés


Découvrir des entreprises performantes dans le passé